Childrens Hospital Los Angeles
- Type
- Teaching hospital
- Where
- Los Angeles, CA
- Medicare CCN
- 053302
- Received
- $6,875,095 in 1,180 records, 2020 ($326,055 general, $6,549,039 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: CHILDRENS HOSPITAL LOS ANGELES Fuzzy (name and state)
- Plan sponsor: CHILDRENS HOSPITAL LOS ANGELES Fuzzy (name and state)
- Lobbying client: CHILDRENS HOSPITAL LOS ANGELES Fuzzy (name and state)
- Lobbying client: CHILDRENS HOSPITAL LOS ANGELES Fuzzy (name and state)
- Lobbying client: CHILDRENS HOSPITAL LOS ANGELES Fuzzy (name and state)
- Lobbying client: CHILDRENS HOSPITAL LOS ANGELES Fuzzy (name and state)
- Nonprofit: CHILDRENS HOSPITAL LOS ANGELES Fuzzy (name and state)
- Trademark owner: Childrens Hospital Los Angeles Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 37 | $326,055 |
| 2020 | Research payment | 1,143 | $6,549,039 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,143 | $6,549,039 |
| Grant | 18 | $300,796 |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing educat | 2 | $15,325 |
| Space rental or facility fees (teaching hospital only) | 4 | $4,075 |
| Honoraria | 1 | $2,191 |
| Education | 2 | $1,771 |
| Charitable Contribution | 3 | $1,107 |
| Gift | 4 | $697 |
| Royalty or License | 3 | $91 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Ultragenyx Pharmaceutical Inc. | $14,810 | Research payment | Cash or cash equivalent | DOJOLVI Drug, Oral nutritional supplements | UX007-CL003 | 2020 |
| 2020-12-31 | AstraZeneca UK Limited | $6,123 | Research payment | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $3,891 | Research payment | In-kind items and services | A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Anti | 2020 | |
| 2020-12-31 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-31 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-31 | Masimo Corporation | $46 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Aimmune Therapeutics, Inc. | $18 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-12-31 | Stryker Corporation | $16 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-29 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-29 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-29 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-28 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-28 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-28 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-28 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-28 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-28 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-28 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-27 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-25 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $2,868 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $2,280 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2020 |
| 2020-12-23 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-23 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-23 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-23 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-23 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $23,967 | Research payment | Cash or cash equivalent | Victoza Biological, Diabetes | NN2211-3659 | 2020 |
| 2020-12-22 | SANOFI US SERVICES INC. | $8,310 | Research payment | Cash or cash equivalent | ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inh | 2020 | |
| 2020-12-22 | Daiichi Sankyo Inc. | $5,875 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176B-D-312 | 2020 |
| 2020-12-22 | Daiichi Sankyo Inc. | $1,533 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176B-D-312 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $1,500 | Research payment | Cash or cash equivalent | Victoza Biological, Diabetes | NN2211-3659 | 2020 |
| 2020-12-22 | Daiichi Sankyo Inc. | $1,421 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176B-D-312 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $1,351 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | Victoza Biological, Diabetes | NN2211-3659 | 2020 |
| 2020-12-22 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-22 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-22 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-21 | Boston Scientific Corporation | $200 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-21 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-21 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-21 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-20 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-18 | Neurelis, Inc. | $8,957 | Research payment | Cash or cash equivalent | VALTOCO Drug, EPILEPSY | A 12-Month, Open Label, Repeat-Dose Safety Study Of NRL-1IN Epilepsy Subjects | 2020 |
| 2020-12-18 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-17 | PTC Therapeutics, Inc. | $4,711 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE | 2020 | |
| 2020-12-17 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-17 | Boston Scientific Corporation | $200 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-17 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-16 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-16 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-16 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-16 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-15 | Luminex Corporation | $2,700 | Compensation for serving as faculty or as a speaker for an accredited or certified continuing educat | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | PFIZER INC. | $1,727 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-12-15 | PFIZER INC. | $397 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-12-15 | Amgen Inc. | $183 | Research payment | In-kind items and services | Prolia Biological, Bone Health | GIOP Pediatric 1 | 2020 |
| 2020-12-14 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-14 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-13 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-12 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-11 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-11 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-11 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-11 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-10 | AQUESTIVE THERAPEUTICS, INC. | $16,470 | Research payment | Cash or cash equivalent | LIBERVANT Drug, Epilepsy | SAFETY AND TOLERABILITY STUDY OF DIAZEPAM BUCCAL SOLUBLE FILM DBSF IN SUBJECTS WITH EPILEPSY | 2020 |
| 2020-12-10 | BioFire Diagnostics, LLC | $2,639 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | BioFire PN1.x Prospective Study | 2020 |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $1,995 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO < | 2020 |
| 2020-12-10 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-10 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-10 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-10 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-10 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-10 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-09 | Genentech, Inc. | $31,287 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | STUDY TO EVALUATE THE SAFETY EFFICACY PK AND PD OF EMICUZUMAB IN MILD OR MODERATE HEMOPHILIA A NI | 2020 |
| 2020-12-09 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-09 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-09 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-09 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-09 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $50,369 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2020 |
| 2020-12-08 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-08 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-08 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-08 | Incyte Corporation | $42 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-12-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-12-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-12-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-12-08 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-12-07 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-07 | Amgen Inc. | $183 | Research payment | In-kind items and services | Prolia Biological, Bone Health | GIOP Pediatric 1 | 2020 |
| 2020-12-07 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-07 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-06 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-06 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-06 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-05 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-04 | Genentech, Inc. | $22,345 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | COMPARISON OF BYPASSING AGENTS FEIBA RFVIIA IN PATIENTS ON EMICIZUMAB USING GLOBAL HEMOSTASIS ASSA | 2020 |
| 2020-12-04 | Merck Sharp & Dohme LLC | $2,027 | Research payment | In-kind items and services | ZINPLAVA Biological, INFECTIOUS DISEASE | Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar | 2020 |
| 2020-12-03 | PFIZER INC. | $30,093 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-12-03 | Amgen Inc. | $550 | Research payment | In-kind items and services | Prolia Biological, Bone Health | Pediatric OI. | 2020 |
| 2020-12-03 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-03 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-03 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-03 | PFIZER INC. | $298 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-12-03 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-03 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-02 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-12-02 | ABBVIE INC. | $50 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-292 | 2020 |
| 2020-12-01 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-30 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-30 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-28 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-28 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-27 | Kite Pharma, Inc. | $9,706 | Research payment | Cash or cash equivalent | A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with R | 2020 | |
| 2020-11-27 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-27 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-27 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-26 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-26 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-26 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-25 | Novo Nordisk AS | $1,729 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2020 |
| 2020-11-25 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-25 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-25 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-25 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-24 | Sarepta Therapeutics, Inc. | $10,237 | Research payment | Cash or cash equivalent | Vyondys 53 Drug, Genetic Disease | 4045-301 | 2020 |
| 2020-11-24 | Spark Therapeutics, Inc. | $4,577 | Research payment | Cash or cash equivalent | LUXTURNA Biological, OCULAR | A POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGEN | 2020 |
| 2020-11-24 | Regeneron Pharmaceuticals, Inc. | $2,589 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO < | 2020 |
| 2020-11-24 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-23 | Ultragenyx Pharmaceutical Inc. | $28,373 | Research payment | Cash or cash equivalent | Crysvita Drug, XLH Metabolic Bone Disorder | UX023-CL401 | 2020 |
| 2020-11-23 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-23 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-23 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-20 | Adaptive Biotechnologies Corporation | $26,100 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ONC1401 | 2020 |
| 2020-11-20 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-20 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ONC1401 | 2020 |
| 2020-11-20 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-20 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-20 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-19 | JAZZ PHARMACEUTICALS INC. | $72,500 | Research payment | Cash or cash equivalent | AN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) | 2020 | |
| 2020-11-19 | JAZZ PHARMACEUTICALS INC. | $16,500 | Research payment | Cash or cash equivalent | AN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) | 2020 | |
| 2020-11-19 | Abbott Laboratories | $1,175 | Research payment | Cash or cash equivalent | SJM Masters HP 15mm Rotatable Mechanical Heart Valve Device, Cardiac Arrhythmias and Heart Failure | A Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as | 2020 |
| 2020-11-19 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or | 2020 |
| 2020-11-19 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-18 | Genentech, Inc. | $10,921 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | OPEN LABEL PHASE III STUDY OF EMICIZUMAB IN HEMOPHILIA A PEDIATRICS PATIENTS WITH INHIBITORS | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $1,520 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2020 |
| 2020-11-18 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-17 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-17 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-17 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-17 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-17 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-17 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-16 | Ultragenyx Pharmaceutical Inc. | $9,679 | Research payment | Cash or cash equivalent | Crysvita Drug, XLH Metabolic Bone Disorder | UX023-CL401 | 2020 |
| 2020-11-16 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-16 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-16 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-16 | EMD Millipore Corporation | $41 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-11-15 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-15 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-14 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-14 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-13 | JAZZ PHARMACEUTICALS INC. | $50,811 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2020 |
| 2020-11-13 | Genentech, Inc. | $24,938 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | STUDY TO EVALUATE THE SAFETY EFFICACY PK AND PD OF EMICUZUMAB IN MILD OR MODERATE HEMOPHILIA A NI | 2020 |
| 2020-11-12 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-12 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-12 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-12 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-12 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-11 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $5,292 | Research payment | Cash or cash equivalent | ZOLGENSMA Biological, GENE THERAPY | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | 2020 |
| 2020-11-11 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $1,883 | Research payment | Cash or cash equivalent | ZOLGENSMA Biological, GENE THERAPY | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | 2020 |
| 2020-11-10 | PFIZER INC. | $8,240 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-11-10 | PFIZER INC. | $2,672 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-11-10 | PFIZER INC. | $1,727 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-11-10 | Genentech, Inc. | $1,549 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | EMICIZUMAB MINOR SURGERY | 2020 |
| 2020-11-10 | PFIZER INC. | $1,407 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-11-10 | PFIZER INC. | $496 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-11-10 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-10 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-10 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-10 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-10 | PFIZER INC. | $221 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-11-10 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-09 | Novartis Pharmaceuticals Corporation | $833 | Research payment | In-kind items and services | KYMRIAH Biological, ONCOLOGY | PHASE II PEDIATRIC RELAPSED AND OR REFRACTORY ALL CONFIRMATORY | 2020 |
| 2020-11-09 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-09 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-09 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-09 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-09 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-09 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-08 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-08 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-08 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-08 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-06 | Takeda Pharmaceuticals U.S.A., Inc. | $1,929 | Research payment | Cash or cash equivalent | OPEN LABEL STUDY OF THE EFFICACY AND LONG TERM SAFETY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBI | 2020 | |
| 2020-11-06 | Adaptive Biotechnologies Corporation | $450 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
| 2020-11-05 | Epizyme, Inc. | $6,357 | Research payment | Cash or cash equivalent | TAZVERIK Drug, ONCOLOGY | A PHASE 1 STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN PEDIATRIC SUBJECTS WITH RELAPSED OR REFRACTORY INI1-NEGATIVE TUMOR | 2020 |
| 2020-11-05 | Regeneron Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO < | 2020 |
| 2020-11-05 | Adaptive Biotechnologies Corporation | $150 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PBMTC-ONC-1701 | 2020 |
The latest 200 records of 1,180.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Los Angeles, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) Los Angeles, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 3,857,263 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 3,898,747 | 10,014,009 | 39,538,223 |
| Median age B01002 | 37.2 | 38.2 | 37.9 |
| Under 18 B01001 | 19.2% | 20.6% | 22.0% |
| 65 and over B01001 | 14.2% | 15.2% | 15.7% |
| Households B11001 | 1,439,097 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 35.7% | 33.4% | 27.0% |
| Median household income B19013 | $81,939 | $90,112 | $99,122 |
| Median family income B19113 | $94,546 | $101,573 | $113,346 |
| Per capita income B19301 | $47,685 | $45,792 | $49,513 |
| Poverty rate B17001 | 16.5% | 13.7% | 12.0% |
| Unemployment rate B23025 | 8.2% | 7.3% | 6.6% |
| Civilian labor force B23025 | 2,128,918 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.7 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 38.5% | 36.0% | 37.1% |
| Housing units B25001 | 1,554,332 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 36.0% | 45.9% | 55.9% |
| Renters B25003 | 64.0% | 54.1% | 44.1% |
| Median home value B25077 | $921,200 | $834,200 | $734,700 |
| Median gross rent B25064 | $1,933 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 28.1% | 24.7% | 33.8% |
| Black B03002 | 8.1% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 47.2% | 48.4% | 40.2% |
| Asian B03002 | 11.9% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Los Angeles, CA.
Comments